<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01674946</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 140/11</org_study_id>
    <nct_id>NCT01674946</nct_id>
  </id_info>
  <brief_title>Effect of Bile Acids on the Secretion of Satiation Peptides in Humans</brief_title>
  <official_title>Effect of Intraduodenal Perfusion of Bile Acids on the Secretion of Gastrointestinal Satiation Peptides in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is do determine the functional significance of the G
      protein-coupled receptor TGR5 in the secretion of GI satiation peptides by using natural bile
      acids and oleanolic acid (triterpenoid compound of plant origin) as TGR5 agonists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TGR5 is expressed in GLP-1-secreting cell lines and L cells from mice; gain- and
      loss-of-function models suggest a physiological role for TGR5 activation on GLP-1 secretion
      in rodents. TGR5 signaling showed improved postprandial glucose tolerance in obese mice,
      associated with marked postprandial GLP-1 release and insulin secretion. In contrast, TGR5-/-
      mice exhibited reduced glucose tolerance. In animals, TGR5 activation has been shown for
      natural bile acids (BAs) and triterpenoid compounds of plant origin, such as oleanolic acid
      (OA), suggesting a role for postprandial BAs in modulating nutrient-induced GLP-1 secretion.
      We therefore hypothesized that intraduodenal (ID) perfusions of TGR5 agonists (BAs and OA)
      stimulate the secretion of GLP-1 with respective changes in the glucose metabolism of healthy
      humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal satiation peptide secretion</measure>
    <time_frame>3 hours blood sampling</time_frame>
    <description>Assessment of plasma GLP-1, PYY and CCK release to BA and OA stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum bile acids</measure>
    <time_frame>3 hours blood sampling</time_frame>
    <description>Assessment of serum bile acids levels to BA and OA stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite perceptions during 3 hours using visual analogue scales</measure>
    <time_frame>3 hours</time_frame>
    <description>Assessment of the following appetite perceptions markers: feelings of hunger, feelings of prospective food consumption, feelings of fullness and feelings of satiety using validated visual analogue scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and insulin secretion</measure>
    <time_frame>3 hours blood sampling</time_frame>
    <description>Assessment of plasma glucose and insulin levels to BA and OA stimulation</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Echolocation</condition>
  <arm_group>
    <arm_group_label>ID saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ID saline by feeding tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID saline + CDCA (5 mmol/L)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CDCA = chenodeoxycholic acid (primary bile acid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID + CDCA (15 mmol/L)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CDCA = chenodeoxycholic acid (primary bile acid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID saline + oleanolic acid (1 mmol/L)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ID saline + CDCA (5 mmol/L) + oleic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ID saline + oleic acid (20 mmol/L)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>intraduodenal perfusion</description>
    <arm_group_label>ID saline</arm_group_label>
    <arm_group_label>ID saline + CDCA (5 mmol/L)</arm_group_label>
    <arm_group_label>ID + CDCA (15 mmol/L)</arm_group_label>
    <arm_group_label>ID saline + oleanolic acid (1 mmol/L)</arm_group_label>
    <arm_group_label>ID saline + CDCA (5 mmol/L) + oleic acid</arm_group_label>
    <arm_group_label>ID saline + oleic acid (20 mmol/L)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bile acid (CDCA, chenodeoxycholic acid)</intervention_name>
    <description>intraduodenal perfusion</description>
    <arm_group_label>ID saline + CDCA (5 mmol/L)</arm_group_label>
    <arm_group_label>ID + CDCA (15 mmol/L)</arm_group_label>
    <arm_group_label>ID saline + CDCA (5 mmol/L) + oleic acid</arm_group_label>
    <other_name>primary bile acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oleanolic acid</intervention_name>
    <description>intraduodenal perfusion</description>
    <arm_group_label>ID saline + oleanolic acid (1 mmol/L)</arm_group_label>
    <other_name>triterpenoid compound of plant origin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>oleic acid</intervention_name>
    <description>intraduodenal perfusion</description>
    <arm_group_label>ID saline + CDCA (5 mmol/L) + oleic acid</arm_group_label>
    <arm_group_label>ID saline + oleic acid (20 mmol/L)</arm_group_label>
    <other_name>fatty acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  BMI of 19.0-24.5

          -  Age 18-40

          -  Stable body weight for at least 3 months

        Exclusion Criteria:

          -  Smoking

          -  Substance abuse

          -  Regular intake of medication

          -  Medical of psychiatric illness

          -  Gastrointestinal disorders or food allergies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Phase 1 Research Unit, Basel Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Phase 1 Research Unit</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2012</study_first_submitted>
  <study_first_submitted_qc>August 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <last_update_submitted>August 24, 2012</last_update_submitted>
  <last_update_submitted_qc>August 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GI-physiology</keyword>
  <keyword>CDCA</keyword>
  <keyword>bile acids</keyword>
  <keyword>TGR5</keyword>
  <keyword>satiation peptides</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

